Researchers refined a DNA base-editing technology to make it more precise. Cystic fibrosis can result from more than 1,000 different mutations, and many genetic diseases need very specific therapies. A common problem for base editors is unintended "bystander" mutations when nearby DNA letters are changed by accident.
The team modified the molecular linker between the editor parts and weakened how strongly the editor binds to DNA. In human cell tests the redesigned editor dramatically reduced bystander edits. The most accurate variant lowered bystander mutations by more than 80% while keeping strong activity at the intended site. At several cystic fibrosis-related sites, unintended edits fell from about 50–60% to under 1% while largely preserving the desired correction.
The work is at an early preclinical stage. More precise editors could help create accurate cell models, test drugs and support more personalised genetic medicine.
Difficult words
- base-editing — a method to change DNA letters directly
- mutation — a change in the DNA sequencemutations
- bystander — a nearby unintended change in DNA
- linker — a small molecule connecting two protein parts
- bind — to attach to DNA or another moleculebinds
- variant — a different form or version of something
- preclinical — before tests in humans begin
- personalised — designed to match one person's needs
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- How could more precise editors help patients with diseases that have many different mutations?
- Why is it useful to create accurate cell models when testing new drugs?
- What concerns or benefits would you expect from genetic medicine at an early preclinical stage?
Related articles
Alternative splicing linked to mammal lifespan
A study in Nature Communications compared alternative splicing across 26 mammal species (lifespans 2.2–37 years) and found splicing patterns better predict maximum lifespan than gene activity; the brain shows many lifespan-linked events controlled by RNA-binding proteins.
New device measures blood viscosity in real time
Researchers at the University of Missouri created a non-invasive device that monitors blood viscosity and density in real time using ultrasound and software. It can read blood without drawing samples and may help in diseases like sickle cell.